NTRA — Natera, Inc.

Nasdaq · Health Care · Health Care Providers & Services · CIK 1604821 ·
Last close
$234.76
Market Cap
$33.62B
52W High
$240.72
52W Low
$181.00
ADV30
1,486,127
Next earnings
2026-08-06
Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide. It offers Signatera, a personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of treatment response in patients previously diagnosed with cancer; Latitude, a blood-based MRD test for colorectal cancer; Altera, a tissue based comprehensive genomic profiling test; and Empower, a hereditary cancer screening test. The company also provides Panorama, a non-invasive prenatal test; Horizon, a carrier screening test; Fetal Focus, a single-gene NIPT, or sgNIPT, that screens for 21 single-gene inherited conditions; and Vistara, a single-gene NIPT, which screens for 25 single-gene conditions. In addition, it offers Anora, which tests and analyzes miscarriage tissue from women who have experienced one or more pregnancy losses; Empower, a hereditary cancer screening test; Prospera, a test to assess active rejection in patients who have undergone solid organ transplantation; Renasight, a kidney gene panel test; and Constellation software, a cloud-based distribution model. Further, the company provides NateraCore, a platform to support the patient and provider experience; phlebotomy services; and EMR integration services. The company serves independent laboratories, national and regional reference laboratories, medical centers and physician practices for its screening tests, research laboratories, and pharmaceutical companies through its direct sales force and laboratory distribution partners, as well as Constellation licensees under its cloud-based distribution model. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays for clinical and commercial use. The company has a collaboration with Diakonos Oncology Corp. to assess molecular response in patients with refractory melanoma. The company was formerly known as Gene Security Network, LLC and changed its name to Natera, Inc. in January 2012. Natera, Inc. was founded in 2003 and is headquartered in Austin, Texas.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 696,644,000 450,833,000 -93,516,000 -85,091,000 2,614,398,000 1,087,932,000 840,380,000
Dec 2025 665,498,000 445,427,000 -22,785,000 47,258,000 2,398,344,000 1,076,140,000 685,931,000
Sep 2025 592,183,000 384,382,000 -97,576,000 -87,544,000 1,821,482,000 1,041,438,000 569,294,000
Jun 2025 546,600,000 346,604,000 -110,372,000 -100,938,000 1,757,066,000 1,000,021,000 510,884,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$211,020,000
Investing CF
$-147,531,000
Financing CF
$50,675,000
CapEx
$-139,510,000
Dividends Paid
Buybacks
EPS Diluted TTM
$-2.48
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$-2,861,113,000
Inventory
$70,721,000
Receivables
$417,595,000
ST Investments
EBIT TTM
$-282,177,000
Pretax Income TTM
$-286,134,000
Interest Exp TTM
$3,957,000
Analysts
18

Yahoo Snapshot (yfinance, live)

Total Revenue
$2,500,926,976
EBITDA
$-267,576,992
Free Cash Flow
$136,918,256
Enterprise Value
$32,773,392,384
Total Cash
$1,087,932,032
Total Debt
$240,080,992
Shares Out
143,215,382
Trailing EPS
$-1.62
Book Value
$12.43
ROE
-15.0%
ROA
-9.1%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 2,306,113,000 -309,911,000 -208,160,000 2,398,344,000 685,931,000 215,301,000
Dec 2024 1,696,911,000 -222,294,000 -190,426,000 1,660,735,000 465,315,000 135,664,000
Dec 2023 1,082,571,000 -446,245,000 -434,801,000 1,441,699,000 676,372,000 -246,955,000
Dec 2022 820,222,000 -541,040,000 -547,799,000 1,394,474,000 688,730,000 -431,501,000

TTM Snapshot

Revenues TTM
NetIncome TTM
OpCashFlow TTM
Assets (Latest)
Forward EPS
$-0.21

Max Pain — expiry 2026-07-17

max pain strike: $220.00 · spot: $262.45 · call oi: 4,832 · put oi: 1,552
Expected Move to 2026-07-17: ±$75.50 (28.77%) — implied range $186.95$337.95 · ATM straddle on $260.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
DGX QUEST DIAGNOSTICS INC $21.83B $197.18
LH LABCORP HOLDINGS INC. $21.20B $258.59
GH Guardant Health, Inc. $17.35B $130.83
THC TENET HEALTHCARE CORP $15.58B $180.88
DVA DAVITA INC. $13.54B $210.93

News headlines (Yahoo Finance, 1h cache)

Natera Flashes A Buy Signal. Why Shares Just Leaped By Double Digits.
2026-06-24 16:48 · Yahoo
Why Natera (NTRA) Is Up 6.7% After Japan Approves First MRD Test for Colorectal Cancer
2026-06-24 10:13 · Yahoo
Signatera™ Receives Regulatory Approval in Japan for Colorectal Cancer
2026-06-24 09:00 · Yahoo
Natera (NTRA) Teams With Pirche To Link Transplant Risk And Prospera Monitoring
2026-06-24 08:09 · Yahoo
Natera (NTRA) Stock Fair Value Edges Lower As MRD And Signatera Debate Splits Analysts
2026-06-23 18:16 · Yahoo
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Tuesday as AI Spending Concerns Weigh on Technology Shares
2026-06-23 13:19 · Yahoo
NCCN Recommends ctDNA-MRD Testing Using Signatera™ Technology in Landmark Bladder Cancer Guideline Update
2026-06-23 10:00 · Yahoo
Pirche Announces Partnership to Advance Transplant Medicine by Combining Pre-Transplant Risk Stratification and Post-Transplant dd-cfDNA Monitoring
2026-06-19 19:06 · Yahoo
Natera to Showcase Organ Health Leadership with 21 Presentations at the American Transplant Congress
2026-06-18 10:00 · Yahoo
Natera (NTRA), CytoDyn Announce Strategic Collaboration for ctDNA-Guided mCRC Clinical Trials
2026-06-17 13:45 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.